ATE328590T1 - Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan - Google Patents

Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan

Info

Publication number
ATE328590T1
ATE328590T1 AT97927353T AT97927353T ATE328590T1 AT E328590 T1 ATE328590 T1 AT E328590T1 AT 97927353 T AT97927353 T AT 97927353T AT 97927353 T AT97927353 T AT 97927353T AT E328590 T1 ATE328590 T1 AT E328590T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
aminoindane
propargyl
disease
compositions containing
Prior art date
Application number
AT97927353T
Other languages
German (de)
English (en)
Inventor
Ruth Levy
Moussa B H Youdim
John P M Finberg
Sasson Cohen
Jeff Sterling
Original Assignee
Teva Pharma
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Technion Res & Dev Foundation filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE328590T1 publication Critical patent/ATE328590T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97927353T 1996-07-11 1997-06-20 Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan ATE328590T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Publications (1)

Publication Number Publication Date
ATE328590T1 true ATE328590T1 (de) 2006-06-15

Family

ID=11069065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927353T ATE328590T1 (de) 1996-07-11 1997-06-20 Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan

Country Status (12)

Country Link
US (1) US6277886B1 (cg-RX-API-DMAC10.html)
EP (1) EP0929298B1 (cg-RX-API-DMAC10.html)
JP (1) JP4368421B2 (cg-RX-API-DMAC10.html)
CN (1) CN1149985C (cg-RX-API-DMAC10.html)
AT (1) ATE328590T1 (cg-RX-API-DMAC10.html)
AU (1) AU3188097A (cg-RX-API-DMAC10.html)
CA (1) CA2260037C (cg-RX-API-DMAC10.html)
DE (1) DE69736066T2 (cg-RX-API-DMAC10.html)
HU (1) HU226961B1 (cg-RX-API-DMAC10.html)
IL (1) IL118836A (cg-RX-API-DMAC10.html)
NO (1) NO326052B1 (cg-RX-API-DMAC10.html)
WO (1) WO1998002152A1 (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
WO2002069977A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
CA2505476C (en) * 2002-11-07 2015-05-26 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US7396860B2 (en) 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
WO2005051371A1 (en) 2003-11-25 2005-06-09 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
SI1848415T1 (sl) * 2005-02-17 2013-08-30 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
KR20170023211A (ko) 2005-02-23 2017-03-02 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CA2634166C (en) 2005-12-09 2016-03-29 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
KR101077835B1 (ko) * 2006-12-14 2011-10-28 테바 파마슈티컬 인더스트리즈 리미티드 라사길린의 타닌산염
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
SG187455A1 (en) * 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
RU2607595C2 (ru) 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
WO2012015950A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
EA201490761A1 (ru) 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU1867095A (en) * 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
EP0929298A1 (en) 1999-07-21
WO1998002152A1 (en) 1998-01-22
IL118836A (en) 2001-01-11
HUP9904525A3 (en) 2000-12-28
HUP9904525A2 (hu) 2000-11-28
CA2260037A1 (en) 1998-01-22
NO990088D0 (no) 1999-01-08
CN1227486A (zh) 1999-09-01
JP4368421B2 (ja) 2009-11-18
CN1149985C (zh) 2004-05-19
NO990088L (no) 1999-03-10
CA2260037C (en) 2007-01-23
JP2000514453A (ja) 2000-10-31
AU3188097A (en) 1998-02-09
HU226961B1 (en) 2010-03-29
EP0929298B1 (en) 2006-06-07
DE69736066T2 (de) 2006-12-28
US6277886B1 (en) 2001-08-21
NO326052B1 (no) 2008-09-08
DE69736066D1 (de) 2006-07-20
IL118836A0 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
ATE328590T1 (de) Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan
HU913447D0 (en) Medical preparations and their use in treating neurologic disorders
NL300205I1 (nl) N-enentiomeer van N-propargyl-1-aminoindaan voor de behandeling van verschillende ziekten, en mesylaat, esylaat en sulfaat daarvan.
GB2254784B (en) Film-coated solid dosage form of anti-migraine drug
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
MX9708977A (es) Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.
CA2122058A1 (en) Tgf-beta to improve neural outcome
CA2111836A1 (en) Spin-trapping pharmaceutical compositions and methods for use thereof
MX9603489A (es) Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos.
CA2148194A1 (en) Cyclopeptides of the formula i
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
ATE202709T1 (de) Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
DE69835435D1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
CA2374997A1 (en) Il6ril6 chimera for the treatment of neurodegenerative diseases
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
CA2097878A1 (en) Therapeutic agent for neutropenia
NZ268039A (en) Use of efaroxan in treating parkinson's disease
RU93004536A (ru) Лекарство для профилактики и терапии неврологических и психиатрических нарушений, возникающих при употреблении алкоголя
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties